RxDoctor Payments DataLook up a doctor →

Day Lennep, MD

Internal Medicine · Jackson, MSNPI 1538509955

Payments from drug & device makers

$12,548in general payments, 2019–2025

Across 695 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • UCB, Inc.$1K
  • Novartis$1K
  • GSK$676
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$400%
  • Food & beverage$12,22797%
  • Education$2812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,548 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,863,734
Medicare patients
521
Services billed
153,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase26$787,118
Humira(Cf) PenAdalimumab50$357,833
Enbrel SureclickEtanercept35$256,719
EnbrelEtanercept16$117,996
OctagamImmun Globg(Igg)/Malt/Iga Ov5011$89,474
ActemraTocilizumab17$54,608
ProliaDenosumab18$31,278
Hydroxychloroquine Sulfate250$8,100
MethotrexateMethotrexate Sodium211$3,525
Leflunomide53$1,921
Mycophenolate Mofetil28$1,704
Azathioprine26$1,007
Prednisone124$900
Duloxetine Hcl29$831
Pilocarpine Hcl18$724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa, Enbrel, Prolia$2,757$936,39260 claims
PfizerOctagam$482$89,47411 claims
Genentech, Inc.Actemra$16$54,60817 claims
Fresenius Kabi USA, LLCSodium Chloride$223$4921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →